Sensei Biotherapeutics Inc. (SNSE), a clinical-stage biotechnology company, on Friday announced first quarter financial results, and provided updates on its developing pipeline.
Q1 2026:
The company reported a net loss of $170.24 million or $131.45 per share, nearly doubled from the first quarter loss of $6.9 million or $5.45 per share in the previous year. The significant Acquired In-Process Research and Development (IPR&D) expenditures totaling $133 million due to the acquisition of Faeth Therapeutics was the main contributor to the higher losses.
R&D expenses amounted to $17.95 million, while in 2025 the same was $3.72 million. G&A expenses also rose to $19.71 million from $3.55 million reported a year ago. The increase in both was primarily attributable to the acquisition of Faeth.
Cash, cash equivalents, and marketable securities held by the company on March 31, 2026, totaled $202.8 million.
Pipeline Updates:
Sensei acquired PIKTOR through the Faeth acquisition, and is developing the investigational, multi-node inhibitor for the treatment of endometrial and breast cancers.
A Phase 1b/2 trial for PIKTOR in treating HR+/HER2- advanced breast cancer is ongoing, with the first patient dosed in April, and interim data expected in 2027. A Phase 2 trial evaluating the drug in treating advanced endometrial cancer is also ongoing, with topline data anticipated for the second half of 2026.
Additionally, the company is developing Solnerstotug in a Phase 1/2 trial for the treatment of advanced solid tumors.
SNSE closed Monday at $19.91, down 2.55%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.